Furthermore, Walk et al. suggest that a statistically sound evaluation of the effects of decreasing homocysteine levels through secondary prevention would have required the observation of ca. 20,000 patients over a period of 5 years [ 65].
A significant uptake of docosahexaenoic acid and eicosapentaenoic acid into the erythrocyte membranes, increased plasma vitamin E levels and decreased homocysteine levels were observed for the active group compared with the control group over the 24-week intervention period (P <0.001, Mann Whitney U test).
The investigators hypothesized that this may be attributed to a drug-specific effect (and not to an anti-inflammatory effect) either by changing levels of adenosine, which is known to interact with glucose and lipid metabolism, or by an indirect effect mediated through concomitant folic acid administration, thereby decreasing homocysteine levels.
This result was in contrast to the previous trials which investigated vitamin supplementation of 2 mg folic acid, 25 mg of vitamin B6 and 400 μg of vitamin B12 and reported significant decrease in homocysteine levels as well as migraine associated symptoms compared to the placebo group at the end of treatment period.
Similarly, overexpression of Cbs in DS patients leads to a decrease in homocysteine levels (37).
We then used an adenoviral construct designed to restrict expression of DYRK1A to hepatocytes, and found decreased plasma homocysteine levels after hepatocyte-specific Dyrk1a gene transfer in hyperhomocysteinemic mice.
Commensurate with the decreased plasma homocysteine levels, targeted hepatic expression of DYRK1A resulted in elevated plasma paraoxonase-1 activity and apolipoprotein A-I levels, and rescued the Akt/GSK3 signaling pathways in aorta of mice, which can prevent homocysteine-induced endothelial dysfunction.
In children with CF we demonstrate that 5-MTHF and vitamin B12 supplementation (i) increases plasma and red cell folate levels; (ii) decreases plasma homocysteine levels; (iii) modifies red cell membrane fatty acid composition; (iv) increases red cell K+ content; (v) reduces red cell membrane oxidative damage; and HSP70 membrane association.
In CF children, 5-MTHF and vitamin B12 supplementation (i) increased plasma and RBC folate levels; (ii) decreased plasma homocysteine levels; (iii) modified RBC membrane phospholipid fatty acid composition; (iv) increased RBC K+ content; (v) reduced RBC membrane oxidative damage and HSP70 membrane association.
Our results might give clues to understand the protective effect of Down syndrome against vascular defect through a decrease of homocysteine level by DYRK1A over-expression.
